NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Larotrectinib (Primary) ; Larotrectinib (Primary)
- Indications CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Glioma; Langerhans cell histiocytosis; Medulloblastoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 09 Apr 2018 Planned End Date changed from 31 Mar 2022 to 30 Sep 2024.
- 09 Apr 2018 Planned primary completion date changed from 31 Mar 2022 to 30 Sep 2024.
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.